Lynnette Fallon Sells 5,091 Shares of ClearPoint Neuro (NASDAQ:CLPT) Stock

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Director Lynnette Fallon sold 5,091 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $11.14, for a total value of $56,713.74. Following the transaction, the director directly owned 48,227 shares in the company, valued at $537,248.78. This represents a 9.55% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

ClearPoint Neuro Stock Down 2.2%

Shares of NASDAQ CLPT opened at $11.44 on Friday. ClearPoint Neuro, Inc. has a one year low of $8.27 and a one year high of $30.10. The company has a debt-to-equity ratio of 2.63, a current ratio of 5.79 and a quick ratio of 4.88. The business’s fifty day moving average price is $10.55 and its 200-day moving average price is $12.79. The stock has a market capitalization of $343.09 million, a PE ratio of -11.33 and a beta of 1.29.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). ClearPoint Neuro had a negative net margin of 71.57% and a negative return on equity of 140.96%. The firm had revenue of $12.13 million for the quarter, compared to analysts’ expectations of $11.97 million. On average, equities research analysts anticipate that ClearPoint Neuro, Inc. will post -1.05 EPS for the current year.

Analysts Set New Price Targets

CLPT has been the topic of a number of recent research reports. B. Riley Financial upped their price target on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Stifel Nicolaus assumed coverage on ClearPoint Neuro in a report on Friday, May 8th. They set a “buy” rating and a $16.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ClearPoint Neuro in a report on Monday, April 20th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $18.00.

Institutional Trading of ClearPoint Neuro

A number of institutional investors have recently added to or reduced their stakes in CLPT. Millennium Management LLC lifted its holdings in ClearPoint Neuro by 156.3% during the 1st quarter. Millennium Management LLC now owns 741,193 shares of the company’s stock worth $8,813,000 after purchasing an additional 452,043 shares in the last quarter. SG Americas Securities LLC purchased a new stake in ClearPoint Neuro during the 1st quarter worth about $3,388,000. FirstWave Capital Management LLC purchased a new stake in ClearPoint Neuro during the 4th quarter worth about $4,971,000. Two Sigma Investments LP lifted its holdings in ClearPoint Neuro by 1,316.1% during the 3rd quarter. Two Sigma Investments LP now owns 310,526 shares of the company’s stock worth $6,766,000 after purchasing an additional 288,598 shares in the last quarter. Finally, Boone Capital Management LLC purchased a new stake in ClearPoint Neuro during the 3rd quarter worth about $6,186,000. Hedge funds and other institutional investors own 30.08% of the company’s stock.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.